Related Experiment Video
Updated: Jan 26, 2026

Fecal Microbiota Transplantation via Colonoscopy for Recurrent C. difficile Infection
Published on: December 8, 2014
[Customised infectiology - Fecal microbiota transplantation : following the Clostridioides difficile pathway]
Tatiana Katerina Galperine1, Benoît Guery1
1Service des maladies infectieuses, CHUV, 1011 Lausanne.
Abstract:
Fecal microbiota transplantation (FMT) raised, in the recent years, a growing interest, mostly in Clostridioides difficile infections (CDI). The concept of FMT is quite simple based on the administration of fecal matter from a healthy donor to a patient with a disease related to the gut microbiota imbalance (dysbiosis). Although the theory seems straightforward, the fine mechanisms are multiple and not yet completely understood. In Switzerland, FMT is considered as a drug under the pharmacist responsibility. The only official indication for FMT is multi-recurrent CDI. For practical reasons, most of the FMT are performed with fresh stools, but development of frozen forms and capsules should considerably enhance treatment delivery. Other indications are currently investigated but not yet in the clinical routine.
Insights
Fecal microbiota transplantation (FMT) is a promising treatment for recurrent Clostridioides difficile infections (CDI). While its mechanisms require further study, FMT offers a viable therapeutic option for gut dysbiosis.
Area of Science:
- Gastroenterology and Microbiology
- Pharmacology and Drug Regulation
Background:
- Fecal microbiota transplantation (FMT) has gained significant interest for treating conditions linked to gut dysbiosis.
- Clostridioides difficile infections (CDI) are a primary focus for FMT application.
Purpose of the Study:
- To provide an overview of Fecal microbiota transplantation (FMT) in the context of Clostridioides difficile infections (CDI).
- To discuss the regulatory status and practical considerations of FMT in Switzerland.
- To highlight ongoing research into alternative FMT delivery methods and indications.
Main Methods:
- Literature review and synthesis of current knowledge on FMT.
- Analysis of the regulatory framework for FMT in Switzerland.
- Discussion of clinical applications and future research directions.
Main Results:
- FMT is primarily indicated for multi-recurrent CDI in Switzerland, regulated as a drug.
- The precise mechanisms of FMT action are not fully elucidated.
- Frozen FMT preparations and capsules are being developed to improve treatment accessibility.
Conclusions:
- FMT is an established treatment for recurrent CDI, with potential for broader applications.
- Regulatory oversight and innovative delivery methods are crucial for expanding FMT use.
- Continued research is necessary to understand FMT's mechanisms and optimize its therapeutic potential.
Related Concept Videos
C4 Pathway and CAM
C4 Pathway
The C4 pathway is used by plants such as...
Other Glycolytic Pathways
Respiration Pathways
Auditory Pathway
When viewed cross-sectionally, the cochlea reveals the scala vestibuli and scala tympani flanking...
ER Retrieval Pathway
The ER uses many checkpoints to prevent the entry of incorrectly folded or a resident protein as cargo onto a transport vesicle. These mechanisms...
Indirect Motor Pathways
The vestibulospinal tract originates in the vestibular nuclei of the brainstem. The vestibular system detects changes in...

